|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Targeting proteins involved in vesicular transport like Rab GTPases, the neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9), runt-related transcription factor 2 (RUNX2), human rhomboid family-1 (RHBDF1), monocarboxylate transporter 4, etc., would aid in designing improved therapeutics for the treatment of breast cancer.
|
31828433 |
2020 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.
|
30051648 |
2018 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
High expression of MCT1 and MCT4 in tumour tissues was associated with poor patient outcome; further the correlation between MCT1 expression and poor prognosis in breast cancer was further strengthened when combined with MCT4 overexpression in the adjacent adipose tissue.
|
29775610 |
2018 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
We found that breast carcinoma cells that prefer bone as a metastatic site have very high extracellular proton efflux and expression of pumps/ion transporters associated with acid-base balance (MCT4, CA9, and V-ATPase).
|
28903357 |
2017 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
NAC as a single agent reduces MCT4 stromal expression, which is a marker of glycolysis in breast cancer with reduced carcinoma cell proliferation.
|
29248134 |
2017 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
These results suggest that MCT4 is a potential therapeutic target in defined breast cancer subtypes and reveal novel avenues for combination treatment.
|
25965974 |
2015 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Here, we used MCT4 immuno-staining of human breast cancer tissue microarrays (TMAs; > 180 triple-negative patients) to directly assess the prognostic value of the "Reverse Warburg Effect."
|
22313602 |
2012 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
The goal of the present work was to evaluate the correlation of glucose transporter 1 (GLUT1) and carbonic anhydrase IX (CAIX) with the monocarboxylate transporters 1 (MCT1) and 4 (MCT4) and their chaperone, CD147, in breast cancer.
|
21870331 |
2011 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Targeting proteins involved in vesicular transport like Rab GTPases, the neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9), runt-related transcription factor 2 (RUNX2), human rhomboid family-1 (RHBDF1), monocarboxylate transporter 4, etc., would aid in designing improved therapeutics for the treatment of breast cancer.
|
31828433 |
2020 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
High expression of MCT1 and MCT4 in tumour tissues was associated with poor patient outcome; further the correlation between MCT1 expression and poor prognosis in breast cancer was further strengthened when combined with MCT4 overexpression in the adjacent adipose tissue.
|
29775610 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
NAC as a single agent reduces MCT4 stromal expression, which is a marker of glycolysis in breast cancer with reduced carcinoma cell proliferation.
|
29248134 |
2017 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
These results suggest that MCT4 is a potential therapeutic target in defined breast cancer subtypes and reveal novel avenues for combination treatment.
|
25965974 |
2015 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
CTD_human |
Here, we used MCT4 immuno-staining of human breast cancer tissue microarrays (TMAs; > 180 triple-negative patients) to directly assess the prognostic value of the "Reverse Warburg Effect."
|
22313602 |
2012 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
The goal of the present work was to evaluate the correlation of glucose transporter 1 (GLUT1) and carbonic anhydrase IX (CAIX) with the monocarboxylate transporters 1 (MCT1) and 4 (MCT4) and their chaperone, CD147, in breast cancer.
|
21870331 |
2011 |
|
Malignant neoplasm of stomach
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In GC cell lines, MCT1, 2, and 4 were up-regulated with different expression levels; MCT1 and MCT4 were more widely expressed in GC cell lines compared with MCT2.
|
27224918 |
2016 |
|
Malignant neoplasm of stomach
|
0.310 |
Biomarker
|
disease |
CTD_human |
In GC cell lines, MCT1, 2, and 4 were up-regulated with different expression levels; MCT1 and MCT4 were more widely expressed in GC cell lines compared with MCT2.
|
27224918 |
2016 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
|
27224918 |
2016 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
|
27224918 |
2016 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Using the ""reverse Warburg effect"" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers."
|
22313602 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness.
|
31395464 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Candidate inhibitors 1-9 have been evaluated for <i>in vitro</i> cell proliferation against MCT1 and MCT4 expressing cancer cell lines.
|
31040927 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo <sup>13</sup> C MRSI studies of orthotopic tumors in mice also showed a significant 52% decrease in hyperpolarized [1-<sup>13</sup> C]Lac/Pyr when comparing vorinostat-treated U87 GBM tumors with controls, and, as in the cell studies, this metabolic finding was associated with increased MCT1 and MCT4 expression in HDAC-inhibited tumors.
|
30561869 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours.
|
30790227 |
2019 |